THOUSAND OAKS, Calif., Sept. 10, 2023 /PRNewswire/ -- Amgen (AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS ...

The global market for KRAS inhibitors has seen substantial growth in recent years, largely due to the heightened awareness of KRAS mutations as significant contributors to cancer development in ...